RU2019100381A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019100381A3 RU2019100381A3 RU2019100381A RU2019100381A RU2019100381A3 RU 2019100381 A3 RU2019100381 A3 RU 2019100381A3 RU 2019100381 A RU2019100381 A RU 2019100381A RU 2019100381 A RU2019100381 A RU 2019100381A RU 2019100381 A3 RU2019100381 A3 RU 2019100381A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359607P | 2016-07-07 | 2016-07-07 | |
| US62/359,607 | 2016-07-07 | ||
| US201762467478P | 2017-03-06 | 2017-03-06 | |
| US62/467,478 | 2017-03-06 | ||
| PCT/EP2017/067119 WO2018007597A1 (en) | 2016-07-07 | 2017-07-07 | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019100381A RU2019100381A (ru) | 2020-08-11 |
| RU2019100381A3 true RU2019100381A3 (enExample) | 2020-11-23 |
| RU2751483C2 RU2751483C2 (ru) | 2021-07-14 |
Family
ID=59381265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019100381A RU2751483C2 (ru) | 2016-07-07 | 2017-07-07 | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294289B2 (enExample) |
| EP (2) | EP4122955A1 (enExample) |
| JP (2) | JP7046903B2 (enExample) |
| KR (2) | KR102432192B1 (enExample) |
| CN (1) | CN109715658B (enExample) |
| AU (2) | AU2017294551B2 (enExample) |
| BR (1) | BR112019000257A2 (enExample) |
| CA (1) | CA3029877C (enExample) |
| DK (1) | DK3481859T3 (enExample) |
| ES (1) | ES2912559T3 (enExample) |
| HU (1) | HUE058734T2 (enExample) |
| IL (1) | IL264030A (enExample) |
| MX (1) | MX2018016257A (enExample) |
| PL (1) | PL3481859T3 (enExample) |
| PT (1) | PT3481859T (enExample) |
| RU (1) | RU2751483C2 (enExample) |
| SG (1) | SG11201900074WA (enExample) |
| SI (1) | SI3481859T1 (enExample) |
| WO (1) | WO2018007597A1 (enExample) |
| ZA (1) | ZA201900507B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| CA3076396A1 (en) * | 2017-09-20 | 2019-03-28 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
| WO2020243478A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Eye And Ear Infirmary | Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss |
| US11625937B2 (en) * | 2020-04-06 | 2023-04-11 | Toyota Motor Engineering & Manufacturing North America, Inc. | Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| WO2022254319A1 (en) | 2021-06-01 | 2022-12-08 | Pfizer Inc. | Cell culture method for producing sfgfr3 polypeptide |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| DK0833620T3 (da) | 1995-06-12 | 2003-01-13 | Yeda Res & Dev | FGFR3, en markør for mesenkymale progenitorceller |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US20040109850A1 (en) | 2000-12-18 | 2004-06-10 | Neelam Jaiswal | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP2003104908A (ja) | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ATE533853T1 (de) | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| AU2010229994B2 (en) | 2009-03-25 | 2016-08-18 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| EP2478003A4 (en) | 2009-09-15 | 2013-05-29 | Five Prime Therapeutics Inc | HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4 |
| US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| EP2512501A4 (en) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS |
| WO2011088196A2 (en) | 2010-01-14 | 2011-07-21 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| AU2013295805B2 (en) | 2012-07-24 | 2019-05-02 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| KR20150037876A (ko) | 2012-07-27 | 2015-04-08 | 제넨테크, 인크. | Fgfr3 관련 상태의 치료 방법 |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EA201591324A1 (ru) * | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| EP3242888B8 (en) * | 2015-01-07 | 2021-06-02 | Pfizer Inc. | Soluble fgfr3 decoys for treating skeletal growth disorders |
| RU2751483C2 (ru) | 2016-07-07 | 2021-07-14 | Пфайзер Инк. | Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения |
| CA3076396A1 (en) | 2017-09-20 | 2019-03-28 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
-
2017
- 2017-07-07 RU RU2019100381A patent/RU2751483C2/ru active
- 2017-07-07 SG SG11201900074WA patent/SG11201900074WA/en unknown
- 2017-07-07 HU HUE17742195A patent/HUE058734T2/hu unknown
- 2017-07-07 EP EP22167483.1A patent/EP4122955A1/en not_active Withdrawn
- 2017-07-07 PT PT177421955T patent/PT3481859T/pt unknown
- 2017-07-07 WO PCT/EP2017/067119 patent/WO2018007597A1/en not_active Ceased
- 2017-07-07 CN CN201780049433.8A patent/CN109715658B/zh not_active Expired - Fee Related
- 2017-07-07 AU AU2017294551A patent/AU2017294551B2/en not_active Ceased
- 2017-07-07 SI SI201731158T patent/SI3481859T1/sl unknown
- 2017-07-07 KR KR1020197002602A patent/KR102432192B1/ko active Active
- 2017-07-07 DK DK17742195.5T patent/DK3481859T3/da active
- 2017-07-07 CA CA3029877A patent/CA3029877C/en active Active
- 2017-07-07 ES ES17742195T patent/ES2912559T3/es active Active
- 2017-07-07 PL PL17742195T patent/PL3481859T3/pl unknown
- 2017-07-07 KR KR1020227027503A patent/KR20220122762A/ko not_active Ceased
- 2017-07-07 MX MX2018016257A patent/MX2018016257A/es unknown
- 2017-07-07 JP JP2019500261A patent/JP7046903B2/ja active Active
- 2017-07-07 EP EP17742195.5A patent/EP3481859B1/en active Active
- 2017-07-07 BR BR112019000257A patent/BR112019000257A2/pt not_active IP Right Cessation
-
2018
- 2018-04-02 US US15/943,436 patent/US10294289B2/en active Active
- 2018-12-30 IL IL264030A patent/IL264030A/en unknown
-
2019
- 2019-01-24 ZA ZA2019/00507A patent/ZA201900507B/en unknown
- 2019-05-20 US US16/417,174 patent/US11021528B2/en not_active Expired - Fee Related
-
2021
- 2021-04-20 US US17/234,841 patent/US11697678B2/en active Active
-
2022
- 2022-03-23 JP JP2022046573A patent/JP7348980B2/ja active Active
- 2022-05-02 AU AU2022202906A patent/AU2022202906A1/en not_active Abandoned
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| HZ9A | Changing address for correspondence with an applicant | ||
| HZ9A | Changing address for correspondence with an applicant |